Spots Global Cancer Trial Database for noncontiguous stage ii grade 2 follicular lymphoma
Every month we try and update this database with for noncontiguous stage ii grade 2 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Beta Alethine in Treating Patients With Low-Grade Lymphoma | NCT00007839 | Lymphoma | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | NCT01190449 | Lymphoma | ofatumumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma | NCT00006039 | Lymphoma Small Intestine... | pegylated inter... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | NCT00278161 | Leukemia Lymphoma | Pegfilgrastim Rituximab Cyclophosphamid... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone | NCT00933127 | Lymphoma | DNA analysis polymerase chai... polymorphism an... laboratory biom... | 18 Years - | SWOG Cancer Research Network | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | NCT00110149 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma | NCT00310167 | Lymphoma | radiation thera... | 18 Years - | University College, London | |
| Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma | NCT00784927 | Lymphoma | rituximab cyclophosphamid... dexamethasone lenalidomide | 18 Years - 120 Years | Mayo Clinic | |
| Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | NCT00003356 | Lymphoma | aldesleukin rituximab | 18 Years - 75 Years | University of Rochester | |
| Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | NCT00005626 | Leukemia Lymphoma | Irinotecan | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | NCT01307605 | Lymphoma | Rituximab lenalidomide | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | NCT01045928 | Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac... | lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL | NCT00732498 | Lymphoma | Methylprednisol... Etoposide Cytarabine Cisplatin Rituximab In-Zevalin Y-Zevalin | 18 Years - | University of Arizona | |
| Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | NCT00010192 | B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... | rituximab aldesleukin laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | NCT00117975 | Lymphoma | galiximab rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma | NCT00006252 | Leukemia Lymphoma | fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt... | - 69 Years | Alliance for Clinical Trials in Oncology | |
| Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma | NCT00258336 | Lymphoma | autologous immu... rituximab sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00006721 | Lymphoma | rituximab cyclophosphamid... doxorubicin prednisone vincristine tositumomab | 18 Years - | SWOG Cancer Research Network | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | NCT00551239 | Leukemia Lymphoma | rituximab fludarabine pho... pixantrone dima... | 18 Years - 120 Years | CTI BioPharma | |
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | NCT00411086 | Lymphoma | Rituximab Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | NCT00089115 | Lymphoma | autologous immu... rituximab sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00387959 | Leukemia Lymphoma | filgrastim rituximab cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... umbilical cord ... total-body irra... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma | NCT00014326 | Lymphoma | radiation thera... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00006721 | Lymphoma | rituximab cyclophosphamid... doxorubicin prednisone vincristine tositumomab | 18 Years - | SWOG Cancer Research Network | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | NCT00004084 | Leukemia Lymphoma | indium In 111 L... yttrium Y 90 ep... | 18 Years - | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | NCT00026351 | Leukemia Lymphoma | rituximab pentostatin | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | NCT00110149 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | NCT00411086 | Lymphoma | Rituximab Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003784 | Lymphoma | CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... tositumomab and... | 18 Years - | SWOG Cancer Research Network | |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | NCT00003338 | Lymphoma | immunoscintigra... technetium Tc 9... | 16 Years - 120 Years | Gilead Sciences | |
| Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma | NCT00006039 | Lymphoma Small Intestine... | pegylated inter... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911 | NCT00896922 | Lymphoma | microarray anal... immunohistochem... laboratory biom... | 16 Years - 120 Years | SWOG Cancer Research Network | |
| Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma | NCT00637832 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisolone vincristine sul... yttrium Y 90 ib... | 18 Years - 120 Years | University of Southampton | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | NCT00551239 | Leukemia Lymphoma | rituximab fludarabine pho... pixantrone dima... | 18 Years - 120 Years | CTI BioPharma | |
| Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | NCT01216683 | Lymphoma | rituximab Bendamustin bortezomib lenalidomide | 18 Years - | Eastern Cooperative Oncology Group | |
| A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | NCT00577278 | Graft Versus Ho... Leukemia Lymphoma | rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom... | 18 Years - 69 Years | City of Hope Medical Center | |
| Beta Alethine in Treating Patients With Low-Grade Lymphoma | NCT00007839 | Lymphoma | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma | NCT01682044 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Margina... Stage I Small L... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Margi... Stage III Small... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Margin... Stage IV Small ... | pegfilgrastim rituximab flow cytometry biopsy immunohistochem... western blottin... | 19 Years - | Roswell Park Cancer Institute | |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | NCT02213913 | Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac... | lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom... | 18 Years - | University of Chicago | |
| Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma | NCT00258336 | Lymphoma | autologous immu... rituximab sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | NCT01307605 | Lymphoma | Rituximab lenalidomide | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | NCT01190449 | Lymphoma | ofatumumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | NCT00117975 | Lymphoma | galiximab rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | NCT02037256 | Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac... | bortezomib filgrastim autologous hema... | 18 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL | NCT00274794 | Lymphoma | filgrastim rituximab | 18 Years - | The Cleveland Clinic | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | NCT00551239 | Leukemia Lymphoma | rituximab fludarabine pho... pixantrone dima... | 18 Years - 120 Years | CTI BioPharma | |
| Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma | NCT00003337 | Lymphoma | immunoscintigra... technetium Tc 9... | 16 Years - 120 Years | Gilead Sciences | |
| Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | NCT00004260 | Lymphoma | recombinant int... rituximab | 18 Years - | Mayo Clinic | |
| Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | NCT00425802 | Leukemia Lymphoma | anti-thymocyte ... filgrastim graft-versus-tu... rituximab cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... nonmyeloablativ... total-body irra... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL | NCT00732498 | Lymphoma | Methylprednisol... Etoposide Cytarabine Cisplatin Rituximab In-Zevalin Y-Zevalin | 18 Years - | University of Arizona | |
| Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers | NCT00003658 | Leukemia Lymphoma | filgrastim rituximab cyclophosphamid... pentostatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant | NCT00002657 | Lymphoma Multiple Myelom... | bleomycin sulfa... recombinant int... cyclophosphamid... cytarabine doxorubicin hyd... etoposide methotrexate prednisone vincristine sul... conventional su... radiation thera... | 15 Years - | SWOG Cancer Research Network | |
| Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00112931 | Lymphoma | rituximab No treatment | 18 Years - 120 Years | University College, London | |
| Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma | NCT00720876 | Lymphoma | rituximab vorinostat | 18 Years - | City of Hope Medical Center | |
| Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | NCT00087425 | Leukemia Lymphoma | rituximab bryostatin 1 | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | NCT00003338 | Lymphoma | immunoscintigra... technetium Tc 9... | 16 Years - 120 Years | Gilead Sciences | |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | NCT00003338 | Lymphoma | immunoscintigra... technetium Tc 9... | 16 Years - 120 Years | Gilead Sciences | |
| Beta Alethine in Treating Patients With Low-Grade Lymphoma | NCT00007839 | Lymphoma | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003615 | Lymphoma | denileukin dift... | 18 Years - 120 Years | Eastern Cooperative Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
